- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03120351
Lidocaine 5% Patch (Lidoderm) for the Prevention of Acute and Chest Pain Following Robotic Valve Surgery
Lidocaine 5% Patch (Lidoderm) for the Perioperative Prevention of Acute and Chronic Chest Pain Following Robotic Valve Surgery
The post-thoracotomy pain (PTP) has been defined as persistent or recurrent pain that lasts for at least 2 month after thoracotomy and is associated with surgical incision or its intercostal nerve cutaneous distribution. The latter has a prevalence of about 15% to 20%. In about 80% of the patients such pain is moderate to severe in intensity and is associated with depression and insomnia. According to its characteristics and possible etiology, PTP is part of the neuropathic pain syndromes. Patients describe their chest wall pain as shooting, burning and numbness which are descriptors often seen in other neuropathic pain syndromes. PTP occurs most likely after partial or complete intercostal nerve damage secondary mechanical trauma (nerve traction or compression) during surgery. The concern is that when robotic surgery for minimally invasive approach to the heart valves or vessels such compression and consequent damage may happen to intercostal nerves.
Therapeutic use for a lidocaine patch include post-herpetic neuralgia postthoracotomy pain, stump neuroma pain, intercostal neuralgia, diabetic polyneuropathy, meralgia paresthetica, complex regional pain syndrome, radiculopathy, postmastectomy pain and some other focal peripheral neuropathic pain syndromes. It is an effective and safe topical treatment. Its efficacy demonstrated previously in treatment of intercostal neuralgia and some patients with post-thoracotomy syndrome can be used in treatment of perioperative chest pain related to robotic cardiac surgery. Hypothesis is that the use of topical lidocaine will decrease pain in acute phase after the surgery and decrease intensity of post-thoracotomy pain 6 months after such procedure.
The effect of topical 5% lidocaine will be clinically evaluated through prospective, randomized, placebo, double-blind study. Each patient will be assessed at admission and then, one week after Valve Replacement (Recommended surgical procedures do not included harvesting of leg vessels as this could be a potential confounder). Then, one month, three and six month follow-up for all patients by mailing questionnaires and phone calls.
Upon admission, as well as 1 week, 1month, 3months and 6 months following surgical procedure, the following tests will be performed:
- Pain Disability Index (PDI)
- DASS
- VAS Pain Score
- Opioid use (in MSO4 mg equivalents)
- Global Perceived Effect (GPE) or patient satisfaction
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- consenting patients ≥ 18 years of age
- scheduled for robotic heart surgery
Exclusion Criteria:
Patient will be excluded from this study if they meet any of the following criteria:
- Patients with a history of mental instability or diagnosed with a mental disorder (e.g. Depression, Somatoform Conversion Disorder, Borderline Personality Disorder, etc.)
- Patients addicted to alcohol, narcotics and other illegal substances
- Patients with a known history of sensitivity to local anesthetics of the amide type, or to any other component of the product.
- Patients with severe hepatic disease (assessment by GI specialist)
- Pregnant Patients
- Patients less than 18 years old
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Lidocaine patch 5%
1) Group I: Patients will receive topical 5% lidocaine patches.
Those will be placed to affected area up to three patches as needed for pain 12 hours on and 12 hours off.
They will also receive opioids as needed after the surgery.
Initially, they may receive IV fentanyl repeated clinician boluses, later oxycodone will be given 5-10 mg q4-6 hours as needed for pain.
|
Patients will receive Lidoderm topical 5% lidocaine patches.
Those will be placed to affected area up to three patches as needed for pain 12 hours on and 12 hours off
Other Names:
|
PLACEBO_COMPARATOR: Placebo Patch
2) Group II: Patients will receive placebo patches.
Those will be placed to affected area at dose up to three patches as needed for pain 12 hours on and 12 hours off.
They will also receive opioids as needed after the surgery.
Initially, they may receive IV fentanyl clinician boluses, later oxycodone will be given in doses from 5-10 mg q4-6 hours as needed for pain.
|
2) Group II: Patients will receive placebo patches.
Those will be placed to affected area at dose up to three patches as needed for pain 12 hours on and 12 hours off
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pain Disability Index Score (PDI) at Six Months Following Surgical Procedure
Time Frame: After surgery until postoperative day 7, 30, 90 and 180
|
Pain Disability Index score (PDI) ranges from 0 to 70, with higher scores reflecting higher interference of pain with daily activities.
|
After surgery until postoperative day 7, 30, 90 and 180
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pain
- Neurologic Manifestations
- Chest Pain
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Sensory System Agents
- Anesthetics
- Membrane Transport Modulators
- Anesthetics, Local
- Voltage-Gated Sodium Channel Blockers
- Sodium Channel Blockers
- Lidocaine
Other Study ID Numbers
- 09-379
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Perioperative Chest Pain
-
Clinical Locomotion ScienceOdense University Hospital; University of Southern Denmark; The County of Funen... and other collaboratorsCompletedUndiagnosed Chest Pain | Musculoskeletal Chest Pain | Non-cardiac Chest PainDenmark
-
Academisch Medisch Centrum - Universiteit van Amsterdam...TerminatedFunctional Chest PainNetherlands
-
Benha UniversityCompleted
-
Cairo UniversityCompleted
-
Naestved HospitalBispebjerg HospitalCompletedPerioperative PainDenmark
-
Pfizer's Upjohn has merged with Mylan to form Viatris...Terminated
-
Atatürk UniversityCompletedPain, Acute | Pain, ChestTurkey
-
Queen's UniversityCompletedChest Pain Atypical SyndromeCanada
-
Universiti Sains MalaysiaCompletedNon Cardiac Chest PainMalaysia
-
Milton S. Hershey Medical CenterCompletedNoncardiac Chest Pain (NCCP)United States
Clinical Trials on Lidoderm 5 % Topical Patch
-
Oregon Health and Science UniversityCompleted
-
University of California, San FranciscoCompleted
-
Endo PharmaceuticalsCompletedChronic Low Back PainUnited States
-
Scilex Pharmaceuticals, Inc.Completed
-
Northwell HealthSolace Brands, Inc.WithdrawnOsteoarthritis | Knee Osteoarthritis | CBDUnited States
-
Endo PharmaceuticalsCompletedOsteoarthritis of the KneeUnited States
-
Scilex Pharmaceuticals, Inc.Completed
-
Frontier Biotechnologies Inc.CompletedChronic Low Back PainChina
-
Hisamitsu Pharmaceutical Co., Inc.Completed
-
Coloplast A/SCompleted